General Pathology — MCQs
On this page
Dohle bodies are what?
In familial Mediterranean fever, which protein undergoes mutation?
Which of the following statements is true about tumour markers?
Which of the following is a transcription factor?
Granuloma is an example of which type of hypersensitivity reaction?
Which of the following is NOT a tumor suppressor gene?
Which protein is implicated in Familial Amyloidosis?
Which of the following is an example of an autosomal dominant disorder?
Which of the following features is NOT characteristic of leukoplakia?
What is the critical pH for the initiation of caries in dentin?
General Pathology Indian Medical PG Practice Questions and MCQs
Question 461: Dohle bodies are what?
- A. Lysosomes
- B. Endoplasmic reticulum (Correct Answer)
- C. Mitochondria
- D. Toxic neutrophilic granules
Explanation: **Explanation:** **Dohle bodies** are small, light blue-gray, oval inclusions found in the periphery of the cytoplasm of neutrophils. They represent **remnants of the Rough Endoplasmic Reticulum (RER)** arranged in parallel rows. They are typically seen in states of "left shift" or accelerated granulopoiesis, where the bone marrow rushes the maturation of neutrophils, leaving behind these immature cytoplasmic structures. * **Why Option B is correct:** Ultrastructural studies confirm that Dohle bodies are composed of lamellar rows of rough endoplasmic reticulum. Their basophilic (blue) appearance on Romanowsky stains (like Leishman or Giemsa) is due to the presence of RNA associated with the ribosomes on the RER. * **Why Option A is incorrect:** Lysosomes in neutrophils are represented by primary (azurophilic) and secondary (specific) granules, not by these distinct blue inclusions. * **Why Option C is incorrect:** Mitochondria are not visible as discrete inclusions like Dohle bodies on light microscopy; their dysfunction usually leads to swelling or vacuolation. * **Why Option D is incorrect:** Toxic granules are dark, coarse, purple-black granules representing abnormal primary granules. While they often coexist with Dohle bodies in systemic inflammation, they are biochemically and morphologically distinct. **High-Yield Clinical Pearls for NEET-PG:** 1. **Clinical Associations:** Dohle bodies are classically seen in **severe bacterial infections (sepsis)**, burns, trauma, and pregnancy. 2. **May-Hegglin Anomaly:** This is a triad of **Dohle-like bodies** (larger and more prominent), giant platelets, and thrombocytopenia. 3. **Toxic Changes:** The "Toxic Triad" in neutrophils includes **Dohle bodies, Toxic Granulations, and Cytoplasmic Vacuolation.**
Question 462: In familial Mediterranean fever, which protein undergoes mutation?
- A. Pyrin (Correct Answer)
- B. Perforin
- C. Atrial natriuretic factor
- D. Immunoglobulin light chain
Explanation: **Explanation:** **Familial Mediterranean Fever (FMF)** is an autosomal recessive autoinflammatory disorder characterized by recurrent episodes of fever and serositis (peritonitis, pleuritis, or synovitis) [1]. 1. **Why Pyrin is Correct:** The disease is caused by a mutation in the **MEFV gene** located on chromosome 16, which encodes the protein **Pyrin**. Pyrin is primarily expressed in neutrophils and is a key component of the **inflammasome** complex [1], [2]. Under normal conditions, pyrin regulates the inflammatory response; however, mutated pyrin leads to the uncontrolled activation of **Caspase-1**, resulting in the excessive production of **Interleukin-1̢ (IL-1̢)** [1]. This "cytokine storm" triggers the characteristic febrile attacks. 2. **Analysis of Incorrect Options:** * **Perforin:** This protein is found in the granules of Cytotoxic T-cells and Natural Killer (NK) cells. Mutations in perforin are associated with **Familial Hemophagocytic Lymphohistiocytosis (HLH)**, not FMF. * **Atrial Natriuretic Factor (ANF):** This is the precursor for **Isolated Atrial Amyloidosis**, a localized form of amyloidosis seen in the elderly. * **Immunoglobulin Light Chain:** This is the precursor protein for **AL (Amyloid Light-chain) Amyloidosis**, typically associated with plasma cell dyscrasias like Multiple Myeloma [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Secondary Amyloidosis:** FMF is a major cause of **AA Amyloidosis** (due to chronic elevation of Serum Amyloid A) [1]. This often leads to renal failure, which is the most serious complication. * **Drug of Choice:** **Colchicine** is used for both the treatment of acute attacks and the prevention of amyloidosis. * **Inheritance:** Autosomal Recessive [1]. * **Diagnosis:** Primarily clinical, supported by the presence of the MEFV mutation. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 267-268. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 196. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 266-267.
Question 463: Which of the following statements is true about tumour markers?
- A. Prostate-specific antigen (PSA) is used for prostate cancer. (Correct Answer)
- B. Tumour markers can be used to diagnose residual recurrence of disease.
- C. Tumour markers can be used for the diagnosis of cancer.
- D. CA-19-9 is used for colon cancer.
Explanation: **Explanation:** **1. Why Option A is Correct:** Prostate-specific antigen (PSA) is a glycoprotein produced by the epithelial cells of the prostate gland. It is the most widely used tumor marker for the screening and monitoring of **prostate cancer** [1]. While it can be elevated in benign conditions like BPH or prostatitis, it remains the gold standard biochemical marker for assessing prostate pathology [2]. **2. Why Other Options are Incorrect:** * **Option B & C:** These statements are technically **incomplete or secondary** in the context of this specific question. While tumor markers *can* be used for monitoring recurrence (Option B) and occasionally aid in diagnosis (Option C), they are generally **not used for primary diagnosis** because they lack sufficient sensitivity and specificity [1]. Most tumor markers are elevated in non-neoplastic inflammatory conditions. Their primary clinical utility is in **monitoring response to therapy** and detecting **recurrence**. * **Option D:** **CA-19-9** is the primary marker for **Pancreatic cancer** and cholangiocarcinoma. For **Colon cancer**, the most specific marker is **Carcinoembryonic Antigen (CEA)** [1]. **3. High-Yield Clinical Pearls for NEET-PG:** * **AFP (Alpha-fetoprotein):** Elevated in Hepatocellular Carcinoma (HCC) and Non-seminomatous germ cell tumors (Yolk sac tumor) [1]. * **CA-125:** Marker for Ovarian cancer (Serous cystadenocarcinoma). * **Calcitonin:** Specific marker for Medullary Carcinoma of the Thyroid. * **hCG:** Marker for Choriocarcinoma and Hydatidiform mole. * **S-100:** Marker for Melanoma, Neural tumors, and Langerhans Cell Histiocytosis (LCH). * **Bombesin:** Marker for Small cell carcinoma of the lung and Neuroblastoma. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 346. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 499-500.
Question 464: Which of the following is a transcription factor?
- A. RAS
- B. MYC (Correct Answer)
- C. FOS
- D. GRAP
Explanation: **Explanation:** The correct answer is **MYC** [1]. **1. Why MYC is correct:** MYC is a classic example of a **nuclear transcription factor** [3]. It belongs to a family of proto-oncogenes (*C-MYC, N-MYC, L-MYC*) that code for proteins which bind to specific DNA sequences [1]. Once activated, MYC promotes cell cycle progression by upregulating genes like **Cyclin D2** and **CDK4**, while downregulating growth inhibitors [2]. In pathology, MYC dysregulation is a hallmark of several malignancies, most notably the **t(8;14)** translocation in Burkitt Lymphoma [1]. **2. Why the other options are incorrect:** * **RAS:** This is a **GTP-binding protein (G-protein)** located on the inner cytoplasmic membrane. It acts as a molecular switch in the MAP kinase pathway, transmitting signals from growth factor receptors to the nucleus [2]. It is not a transcription factor itself. * **FOS:** While FOS is indeed a transcription factor (forming the AP-1 complex with JUN), in the context of standard medical examinations and the specific framing of this question, **MYC** is considered the "prototypical" nuclear transcription factor frequently tested. *Note: In some advanced contexts, FOS is also a transcription factor, but MYC is the primary high-yield answer for this category.* * **GRAP:** This is an adapter protein involved in signaling pathways (linking receptors to RAS), not a transcription factor. **3. High-Yield Clinical Pearls for NEET-PG:** * **C-MYC:** Associated with **Burkitt Lymphoma** [t(8;14)] [1]. * **N-MYC:** Associated with **Neuroblastoma** (amplification indicates poor prognosis) [2]. * **L-MYC:** Associated with **Small Cell Carcinoma of the Lung**. * **Transcription Factor Mnemonic:** Remember **"MYC, JUN, FOS, and REL"** as the primary nuclear oncoproteins. * **RAS Mutation:** The most common oncogene mutation in human tumors (especially pancreatic and colon cancers). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 324-325. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 296-297. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 292-293.
Question 465: Granuloma is an example of which type of hypersensitivity reaction?
- A. Type I Hypersensitivity reaction
- B. Type II Hypersensitivity reaction
- C. Type III Hypersensitivity reaction
- D. Type IV Hypersensitivity reaction (Correct Answer)
Explanation: **Explanation:** **Why the correct answer is right:** Granuloma formation is a classic manifestation of **Type IV (Delayed-type) Hypersensitivity** [2, 3]. This reaction is cell-mediated rather than antibody-mediated. It involves the activation of **T-helper 1 (Th1) cells**, which secrete cytokines like **Interferon-gamma (IFN-γ)** [1, 2]. IFN-γ is the key cytokine that activates macrophages, transforming them into **epithelioid cells** [1, 4]. These epithelioid cells may fuse to form multinucleated giant cells (e.g., Langhans giant cells), which are the hallmarks of a granuloma [1, 4]. This process is the body's attempt to wall off an offending agent that is difficult to eradicate, such as *Mycobacterium tuberculosis* [4, 5]. **Why the other options are incorrect:** * **Type I (Immediate):** Mediated by IgE antibodies and mast cell degranulation (e.g., Anaphylaxis, Asthma). * **Type II (Antibody-mediated):** Involves IgG or IgM antibodies binding to fixed antigens on cell surfaces, leading to complement activation or ADCC (e.g., Autoimmune hemolytic anemia, Goodpasture syndrome). * **Type III (Immune-complex):** Caused by the deposition of soluble antigen-antibody complexes in tissues, leading to inflammation (e.g., SLE, Post-streptococcal glomerulonephritis). **High-Yield Clinical Pearls for NEET-PG:** * **Key Cytokine:** IFN-γ is the most important cytokine in granuloma formation [1]. * **TNF-α:** Essential for maintaining the structural integrity of a granuloma. (Anti-TNF drugs can cause the breakdown of granulomas and reactivation of latent TB). * **Common Examples:** Tuberculosis (Caseating), Sarcoidosis (Non-caseating), Leprosy, Cat-scratch disease, and Schistosomiasis. * **Cell types:** Epithelioid cells (activated macrophages) are the defining component of a granuloma [1, 4]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, p. 109. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 173-174. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 216-218. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 198-200. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 218.
Question 466: Which of the following is NOT a tumor suppressor gene?
- A. WT-1
- B. RB
- C. P53
- D. RAS (Correct Answer)
Explanation: **Explanation:** The fundamental concept in oncology involves distinguishing between **Proto-oncogenes** (which promote cell growth) and **Tumor Suppressor Genes (TSGs)** (which inhibit cell growth) [5]. **Why RAS is the correct answer:** **RAS** is a **proto-oncogene**, not a tumor suppressor gene. It encodes a GTP-binding protein that acts as a molecular switch in the MAPK/ERK signaling pathway. When mutated (point mutation), RAS remains permanently in the "active" GTP-bound state, sending continuous growth signals to the nucleus. It is the most commonly mutated proto-oncogene in human tumors (e.g., KRAS in pancreatic and colon cancers). **Why the other options are incorrect:** * **RB (Retinoblastoma gene):** Known as the "Governor of the Cell Cycle," it controls the G1 to S phase transition [1]. Loss of both alleles leads to Retinoblastoma and Osteosarcoma [2]. * **P53 (TP53):** Known as the "Guardian of the Genome," it senses DNA damage and induces cell cycle arrest or apoptosis [4]. It is the most commonly mutated gene in human cancers overall [1]. * **WT-1 (Wilms Tumor 1):** A TSG located on chromosome 11p13. It is essential for normal renal and gonadal development; its inactivation leads to Wilms tumor. **High-Yield Clinical Pearls for NEET-PG:** * **Knudson’s Two-Hit Hypothesis:** Applies to TSGs (both alleles must be inactivated for cancer to develop) [3]. * **RAS Mutation Site:** Most common point mutations occur at codons 12, 13, or 61. * **Li-Fraumeni Syndrome:** Germline mutation of P53 resulting in multiple primary tumors. * **Governor vs. Guardian:** RB is the *Governor*; P53 is the *Guardian* [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 301-302. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 300. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 298-300. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 227-228. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 297-298.
Question 467: Which protein is implicated in Familial Amyloidosis?
- A. Serum amyloid A
- B. b2-microglobulin
- C. Amyloid b peptide
- D. Transthyretin (Correct Answer)
Explanation: **Explanation:** The correct answer is **Transthyretin (TTR)**. Amyloidosis is a group of disorders characterized by the extracellular deposition of misfolded proteins in a cross-̢-pleated sheet configuration [1]. **Why Transthyretin is correct:** Transthyretin is a serum protein that transports thyroxine and retinol. In **Familial Amyloid Polyneuropathies (FAP)**, genetic mutations (most commonly the *Val30Met* mutation) lead to the production of mutant TTR, which is prone to misfolding and depositing as amyloid (ATTR) [1]. Additionally, wild-type TTR can deposit in the hearts of elderly patients, a condition known as **Senile Systemic Amyloidosis** [1], [2]. **Analysis of Incorrect Options:** * **A. Serum Amyloid A (SAA):** This is an acute-phase reactant synthesized by the liver. It leads to **AA Amyloidosis** (Secondary Amyloidosis), which is associated with chronic inflammatory conditions like Rheumatoid Arthritis, Tuberculosis, or Osteomyelitis [2]. * **B. ̢2-microglobulin:** This is a component of MHC Class I molecules. It is the precursor protein in **Hemodialysis-associated amyloidosis**, as it is not effectively filtered by dialysis membranes and deposits in joints and tendon sheaths [1], [2]. * **C. Amyloid ̢ peptide (A̢):** This protein is derived from Amyloid Precursor Protein (APP) and is the hallmark of **Alzheimer’s Disease**, forming cerebral plaques. **High-Yield Clinical Pearls for NEET-PG:** * **Staining:** All amyloids show **Apple-green birefringence** under polarized light when stained with **Congo Red**. * **Most Common Type:** AL Amyloidosis (Light chain) is the most common systemic type (associated with Multiple Myeloma). * **Diagnosis:** Abdominal fat pad biopsy or rectal biopsy are preferred screening sites due to high sensitivity. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 264-266. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 136-140.
Question 468: Which of the following is an example of an autosomal dominant disorder?
- A. G6PD deficiency
- B. Hirschsprung disease
- C. Neurofibromatosis (Correct Answer)
- D. Vitamin D resistant rickets
Explanation: **Explanation:** **Neurofibromatosis (Option C)** is a classic example of an **Autosomal Dominant (AD)** disorder. It is characterized by high penetrance but variable expressivity. NF-1 (von Recklinghausen disease) results from a mutation in the *NF1* gene on chromosome 17, which encodes neurofibromin, a tumor suppressor that regulates the RAS pathway. NF-2 results from a mutation in the *merlin* gene on chromosome 22. **Analysis of Incorrect Options:** * **G6PD Deficiency (Option A):** This is an **X-linked Recessive** disorder. It primarily affects males and is characterized by episodic hemolysis triggered by oxidative stress (e.g., fava beans, infections, or drugs like Primaquine). * **Hirschsprung Disease (Option B):** This condition exhibits **Multifactorial inheritance** with variable penetrance. While associated with mutations in the *RET* proto-oncogene, it does not follow a simple Mendelian AD pattern. * **Vitamin D Resistant Rickets (Option D):** Also known as Hereditary Hypophosphatemic Rickets, this is a rare **X-linked Dominant** disorder. It is one of the few classic examples of X-linked dominant inheritance tested in exams. **NEET-PG High-Yield Pearls:** * **AD Disorders:** Usually involve mutations in **structural proteins** (e.g., Marfan syndrome, Osteogenesis Imperfecta) or **regulatory proteins/receptors** (e.g., Familial Hypercholesterolemia, NF). [1], [2] * **AR Disorders:** Usually involve mutations in **enzymes** (e.g., Phenylketonuria, Alkaptonuria). * **NF-1 Clinical Triad:** Café-au-lait spots, Lisch nodules (iris hamartomas), and neurofibromas. * **NF-2 Hallmark:** Bilateral acoustic neuromas (vestibular schwannomas). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1157-1158. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Central Nervous System, pp. 1318-1319.
Question 469: Which of the following features is NOT characteristic of leukoplakia?
- A. Hyperkeratosis
- B. Plasma cell infiltration within the dermal papillae (Correct Answer)
- C. Clinically, a paint-like patch
- D. A moist shiny lesion
Explanation: **Explanation:** **Leukoplakia** is a clinical term defined by the WHO as a "white patch or plaque that cannot be characterized clinically or pathologically as any other disease." [1] It is a premalignant lesion of the oral mucosa. **Why Option B is the Correct Answer:** Leukoplakia is characterized by epithelial changes and chronic inflammation, but **plasma cell infiltration within the dermal papillae** is not a defining or characteristic feature. While a chronic inflammatory cell infiltrate (mostly lymphocytes) is often seen in the underlying connective tissue, a dense plasma cell infiltrate is more characteristic of conditions like **Plasma Cell Gingivitis** or certain stages of **Syphilis**. Furthermore, the term "dermal papillae" is technically more appropriate for skin; in the oral mucosa, these are referred to as connective tissue papillae. **Analysis of Incorrect Options:** * **Option A (Hyperkeratosis):** This is a hallmark histological feature. It refers to the thickening of the stratum corneum (hyperorthokeratosis or hyperparakeratosis), which gives the lesion its white appearance. [2] * **Option C (Paint-like patch):** Clinically, early or mild leukoplakia often appears as a thin, translucent, or "faintly painted" white patch with irregular borders. * **Option D (Moist shiny lesion):** Because leukoplakia occurs on mucosal surfaces (which are non-keratinized normally), the accumulation of keratin becomes hydrated by saliva, often resulting in a moist, slightly reflective, or shiny white surface. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Tobacco (most common), alcohol, HPV (16 & 18), and chronic irritation. [1] * **Histopathology:** Ranges from simple hyperkeratosis and acanthosis to varying degrees of **epithelial dysplasia** and carcinoma in situ. [1], [2] * **Malignant Transformation:** Approximately 3–7% of cases progress to Squamous Cell Carcinoma. [1] **Erythroplakia** (red patch) has a much higher malignant potential than leukoplakia. * **Site:** The floor of the mouth and the lateral/ventral tongue have the highest risk of malignant transformation. [2] **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Alimentary System Disease, pp. 344-345. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, pp. 737-738.
Question 470: What is the critical pH for the initiation of caries in dentin?
- A. 4.3-4.5
- B. 5.2-5.5
- C. 4.9-5.1
- D. 6.2-6.5 (Correct Answer)
Explanation: **Explanation:** The concept of **Critical pH** refers to the threshold below which the dental hard tissues begin to demineralize. This value is not uniform across all dental structures because it depends on the mineral content and chemical composition of the tissue. **1. Why Option D is Correct:** Dentin has a significantly lower mineral content (approximately 70% hydroxyapatite) compared to enamel (96%). It also contains more organic matter and carbonate, which makes it more acid-soluble. Consequently, dentin begins to demineralize at a much higher (more neutral) pH than enamel. The critical pH for **dentin and cementum** is typically between **6.2 and 6.7**. Therefore, 6.2–6.5 is the correct range for the initiation of caries in dentin. **2. Why Other Options are Incorrect:** * **Option B (5.2–5.5):** This is the critical pH for **Enamel**. Enamel is highly mineralized and can withstand more acidic environments before the hydroxyapatite crystals begin to dissolve. [1] * **Options A and C (4.3–5.1):** These values represent highly acidic environments. While demineralization occurs rapidly at these levels, they do not represent the *initiation* threshold for dentin. Fluoridated enamel, however, has a lower critical pH (approx. 4.5), making it more resistant to decay. [1] **3. High-Yield Clinical Pearls for NEET-PG:** * **Stephan Curve:** A graph representing the drop and subsequent recovery of plaque pH after consuming carbohydrates. * **Hydroxyapatite vs. Fluorapatite:** Fluoride replaces the hydroxyl ion to form fluorapatite, which lowers the critical pH to ~4.5, providing caries resistance. [1] * **Saliva’s Role:** Saliva acts as a buffer (primarily via bicarbonate) to raise the pH back above the critical threshold and promote remineralization. * **Composition:** Dentin = 70% Inorganic; Enamel = 96% Inorganic. Higher inorganic content = Lower critical pH. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, pp. 734-735.
Practice by Chapter
Cell Injury and Cell Death
Practice Questions
Adaptations of Cellular Growth
Practice Questions
Accumulations and Deposits
Practice Questions
Acute and Chronic Inflammation
Practice Questions
Tissue Repair and Wound Healing
Practice Questions
Hemodynamic Disorders
Practice Questions
Genetic Disorders
Practice Questions
Environmental Pathology
Practice Questions
Nutritional Diseases
Practice Questions
Molecular Basis of Disease
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free